Zydus Lifesciences Limited reported a 36% year-on-year decline in consolidated net profit to ₹9,398 million for Q1FY27, falling short of the estimated ₹10 billion, weighed down by exceptional items including severance provisions and legal settlements. Despite the bottom-line pressure, the company delivered robust top-line growth with consolidated revenue rising 22% to ₹80,170 million, driven by strong performance in its consumer wellness and pharmaceutical segments. The divergence between revenue growth and profit contraction highlights the impact of one-time costs on operational efficiency during the quarter.

The Board of Directors approved the unaudited financial results on August 11, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by Deloitte Haskins & Sells LLP, the statutory auditors. The trading window for designated persons remains closed until August 14, 2026.

Financial Performance

The company's key consolidated financial metrics for Q1FY27 compared to Q1FY26 are presented below:

Standalone net profit declined 12% to ₹3,396 million from ₹3,847 million in Q1FY26. Standalone revenue increased 11% to ₹28,722 million. The consolidated EBITDA margin contracted by 770 basis points year-on-year to 24.07%, reflecting higher employee benefit expenses and R&D costs. Capex (organic) for the quarter was ₹5,852 million.

Exceptional Items and Operational Costs

The profit decline was largely attributable to non-recurring exceptional items totaling ₹182 million in the consolidated results, compared to nil in the prior year period. Key exceptional charges included:

Additionally, the group recognised a one-time increase in gratuity and leave encashment liability of ₹849 million under the New Labour Codes effective November 21, 2025. Employee benefits expenses rose 38.40% YoY to ₹12,491 million, while R&D expenses increased 32.30% to ₹6,424 million, representing 8% of revenues.

Segmental Highlights

The Pharmaceuticals segment contributed ₹60,900 million to revenue, up 8.60% YoY. Within this, India branded formulations grew 20% YoY to ₹18,158 million, outperforming the market in key therapies like Cardiology and Diabetology. The North America business saw sales decline 2.60% YoY to ₹30,979 million but grew sequentially by 4.90%, driven by volume expansion and new launches, including the first biosimilar NUFYMCO™. International Markets revenue surged 34% YoY to ₹9,735 million.

The Consumer Wellness segment emerged as a key growth driver, with the following performance highlights:

Domestic business grew 5% YoY, while international business delivered 25% YoY growth on a like-to-like basis.

Balance Sheet and Key Metrics

While top-line growth remains strong, particularly in high-margin consumer products, the bottom line was pressured by integration costs and legal provisions associated with recent acquisitions like Assertio Holdings. The substantial receipt from Teva helped offset some of these costs. Tax expenses for Q1FY27 are not directly comparable to prior periods due to the remeasurement of deferred tax assets under Section 115BAA of the Income Tax Act, 1961, which provided a gain of ₹515 million in the preceding quarter.

Zydus Lifesciences Limited will participate in the Motilal Oswal 22nd Annual Global Investor Conference on August 18, 2026. The company disclosed this engagement to provide investors with an opportunity to interact with management regarding its strategic direction and business updates. This appearance serves as a key communication channel for stakeholders seeking direct insights from the pharmaceutical firm’s leadership team.

The disclosure was filed with both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) on August 10, 2026. The filing ensures that all exchange members and investors at large are aware of the upcoming investor interaction event.

Event Details

The conference is organized by Motilal Oswal Financial Services. Zydus Lifesciences is scheduled to take part in the proceedings on August 18, 2026. The company did not specify a particular time slot or session format in the initial disclosure.

Regulatory Compliance

The announcement was authorized by Dhal Narenda Soni, Company Secretary and Compliance Officer of Zydus Lifesciences Limited. The filing carries membership number FCS7063 and was digitally signed on August 10, 2026, at 09:37:40 +05'30'.

Zydus Lifesciences Limited maintains its registered office at 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. The company’s Corporate Identification Number (CIN) is L24230GJ1995PLC025878.